Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Total Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has a market cap or net worth of HK$17.24B. The enterprise value is HK$14.83B.
Market CapHK$17.24B
Enterprise ValueHK$14.83B
Share Statistics
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding220,094,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s return on equity (ROE) is 0.03 and return on invested capital (ROIC) is 3.75%.
Return on Equity (ROE)0.03
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.75%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee2.84M
Profits Per Employee177.90K
Employee Count1,926
Asset Turnover0.33
Inventory Turnover0.84
Valuation Ratios
The current PE Ratio of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is 19.6. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s PEG ratio is -0.43.
PE Ratio19.6
PS Ratio1.25
PB Ratio0.57
Price to Fair Value0.57
Price to FCF4.31
Price to Operating Cash Flow9.62
PEG Ratio-0.43
Income Statement
In the last 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H had revenue of 5.48B and earned 349.49M in profits. Earnings per share was 0.24.
Revenue5.48B
Gross Profit1.74B
Operating Income635.97M
Pretax Income402.24M
Net Income349.49M
EBITDA846.59M
Earnings Per Share (EPS)0.24
Cash Flow
In the last 12 months, operating cash flow was 1.73B and capital expenditures -122.50M, giving a free cash flow of 1.61B billion.
Operating Cash Flow1.73B
Free Cash Flow1.61B
Free Cash Flow per Share7.32
Dividends & Yields
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays an annual dividend of HK$0.272, resulting in a dividend yield of 5.23%
Dividend Per ShareHK$0.272
Dividend Yield5.23%
Payout Ratio86.79%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.94
52-Week Price Change23.72%
50-Day Moving Average5.23
200-Day Moving Average5.56
Relative Strength Index (RSI)50.03
Average Volume (3m)1.16M
Important Dates
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H upcoming earnings date is Apr 30, 2026, TBA (Not Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H as a current ratio of 2.31, with Debt / Equity ratio of 17.53%
Current Ratio2.31
Quick Ratio1.19
Debt to Market Cap0.30
Net Debt to EBITDA0.90
Interest Coverage Ratio8.90
Taxes
In the past 12 months, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has paid 59.60M in taxes.
Income Tax59.60M
Effective Tax Rate0.15
Enterprise Valuation
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H EV to EBITDA ratio is 9.01, with an EV/FCF ratio of 4.79.
EV to Sales1.39
EV to EBITDA9.01
EV to Free Cash Flow4.79
EV to Operating Cash Flow4.45
Balance Sheet
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has HK$2.83B in cash and marketable securities with HK$2.11B in debt, giving a net cash position of HK$721.28M billion.
Cash & Marketable SecuritiesHK$2.83B
Total DebtHK$2.11B
Net CashHK$721.28M
Net Cash Per ShareHK$3.28
Tangible Book Value Per ShareHK$6.44
Margins
Gross margin is 31.81%, with operating margin of 11.61%, and net profit margin of 6.38%.
Gross Margin31.81%
Operating Margin11.61%
Pretax Margin7.34%
Net Profit Margin6.38%
EBITDA Margin15.45%
EBIT Margin8.65%
Analyst Forecast
The average price target for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-1.40%
EPS Growth Forecast―